Nevro Corp

Most Recent

  • uploads///medical device business
    Company & Industry Overviews

    What’s ahead for Abbott Laboratories’ Medical Device Unit?

    Abbott Laboratories’ (ABT) Medical Device segment is its largest business division, contributing ~36% to the company’s total sales in 4Q17.

    By Sarah Collins
  • uploads///ABT STJ product portfolio
    Company & Industry Overviews

    These Developments Impacted Abbott Laboratories the Most in Fiscal 2017

    Abbott Laboratories posted a strong earnings results on January 24, surpassing Wall Street estimates and posting earnings at the high end of its guidance.

    By Sarah Collins
  • uploads///vercise
    Company & Industry Overviews

    Boston Scientific Stock Triggered by FDA Approval of Vercise DBS

    On December 11, 2017, Boston Scientific (BSX) stock rose 3%, triggered by FDA approval of its Vercise DBS (deep brain stimulation) system.

    By Sarah Collins
  • uploads///product portfolio
    Company & Industry Overviews

    Inside Abbott’s Neuromodulation Business Growth

    Abbott’s Medical Devices segment has products for rhythm management, heart failure, electrophysiology, structural heart diseases, neuromodulation, and more.

    By Sarah Collins
  • uploads///neuromodulation
    Company & Industry Overviews

    St. Jude’s Proclaim Elite SCS System Received CE Mark Approval

    On December 8, 2016, St. Jude Medical (STJ) announced CE Mark approval for full body MR (magnetic resonance) conditional labeling for the Proclaim Elite SCS (spinal cord stimulation) System.

    By Sarah Collins
  • uploads///capital allocation
    Company & Industry Overviews

    Nevro Lawsuit against BSX Could Impact Its Neuromodulation Revenues

    On November 29, 2016, Nevro Corp. (NVRO) filed a lawsuit against Boston Scientific, claiming patent infringement on its patents for Senza and HF10 spinal cord stimulation therapies for chronic back pain.

    By Sarah Collins
  • uploads///Part  Graph
    Company & Industry Overviews

    How Have IHI’s Mid-Capitalization Stocks Performed?

    On June 9, 2016, the top performer within the mid-capitalization space of the iShares U.S. Medical Devices ETF was Idexx Laboratories, which rose by 1.5%.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    IHI’s Small Caps Outperformed the Market

    Small-cap stocks in the iShares US Medical Devices ETF (IHI) went down by 0.15% and outperformed the SPDR S&P 500 ETF (SPY) and the IHI itself.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.